全文获取类型
收费全文 | 2669篇 |
免费 | 307篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 87篇 |
妇产科学 | 29篇 |
基础医学 | 346篇 |
口腔科学 | 59篇 |
临床医学 | 393篇 |
内科学 | 574篇 |
皮肤病学 | 39篇 |
神经病学 | 232篇 |
特种医学 | 94篇 |
外科学 | 261篇 |
综合类 | 51篇 |
预防医学 | 331篇 |
眼科学 | 33篇 |
药学 | 173篇 |
中国医学 | 8篇 |
肿瘤学 | 236篇 |
出版年
2023年 | 28篇 |
2021年 | 33篇 |
2020年 | 42篇 |
2019年 | 44篇 |
2018年 | 70篇 |
2017年 | 54篇 |
2016年 | 53篇 |
2015年 | 60篇 |
2014年 | 68篇 |
2013年 | 95篇 |
2012年 | 91篇 |
2011年 | 121篇 |
2010年 | 79篇 |
2009年 | 90篇 |
2008年 | 93篇 |
2007年 | 98篇 |
2006年 | 104篇 |
2005年 | 92篇 |
2004年 | 95篇 |
2003年 | 84篇 |
2002年 | 83篇 |
2001年 | 67篇 |
2000年 | 86篇 |
1999年 | 74篇 |
1998年 | 37篇 |
1997年 | 53篇 |
1996年 | 54篇 |
1995年 | 46篇 |
1994年 | 57篇 |
1993年 | 39篇 |
1992年 | 45篇 |
1991年 | 64篇 |
1990年 | 48篇 |
1989年 | 72篇 |
1988年 | 49篇 |
1987年 | 53篇 |
1986年 | 46篇 |
1985年 | 37篇 |
1984年 | 41篇 |
1983年 | 38篇 |
1982年 | 18篇 |
1981年 | 25篇 |
1980年 | 21篇 |
1979年 | 35篇 |
1978年 | 37篇 |
1977年 | 29篇 |
1976年 | 31篇 |
1973年 | 21篇 |
1972年 | 20篇 |
1969年 | 20篇 |
排序方式: 共有2982条查询结果,搜索用时 15 毫秒
51.
Rodney A. Bray Elisabeth Faliex Jean François Allienne Gabriel Mouahid 《Parasitology research》2013,112(12):3981-3989
Lepidapedon sereti n. sp. is described from the macrourid Coelorinchus sereti from the deep water off Vanuatu. It is placed in the Elongatum group and Elongatum subgroup. It differs from the other species described in this subgroup by the distinctly dorsally subterminal excretory pore. It also differs from other species in combinations of size, excretory vesicle length, proportions of forebody, post-testicular region and other metric features. This constitutes the first record of a Lepidapedon (sensu stricto) from the Central Western Pacific Ocean. 相似文献
52.
53.
Enesha M. Cobb William Meurer Deneil Harney Robert Silbergleit Bray Patrick Lake Christina Clark Debbie Gipson William Barsan 《CTS Clinical and Translational Science》2015,8(6):776-778
Objectives
The conference objectives included educating patients and advocates about clinical trials, educating the clinical research community about patient perspectives on participating in clinical trial design, and identifying strategies to increase participation in clinical trial design for neurological disorders.Design
Observations were noted during a 1‐day conference attended by patients, patient advocates, clinical trial staff, and investigators. The conference offered didactic sessions, small, and large group discussions.Participants
Conference participants were patients, patient advocates, clinical trial staff, students, and investigators interested in engaging patients in clinical trial design for neurological disorders.Measures
Conference participants were asked to consider lessons learned that could increase patient engagement in clinical trial design.Results
We found that there is growing interest in including patients in the design of clinical trials for neurological disorders. Several themes emerged on how to move forward: networking; the multifaceted roles of advocates in research; training and education; creating patient–researcher partnerships; and clinical trials regulation issues.Conclusions
The conference provided a forum for dialogue regarding stakeholder engagement in the design of clinical trials for neurological disorders. This experience provides a template for replication and dissemination of this conference and informs next steps to accelerate the pathway from dialogue to action. 相似文献54.
55.
High‐Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms 下载免费PDF全文
R. J. Duquesnoy H. M. Gebel E. S. Woodle P. Nickerson L. A. Baxter‐Lowe R. A. Bray F. H. J. Claas D. D. Eckels J. J. Friedewald S. V. Fuggle J. A. Gerlach J. J. Fung M. Kamoun D. Middleton R. Shapiro A. R. Tambur C. J. Taylor K. Tinckam A. Zeevi 《American journal of transplantation》2015,15(10):2780-2781
56.
L. Cendales R. Bray H. Gebel L. Brewster R. Elbein D. Farthing M. Song D. Parker A. Stillman T. Pearson A. D. Kirk 《American journal of transplantation》2015,15(8):2250-2255
Vascularized composite allotransplantation (VCA) has emerged as a viable limb replacement strategy for selected patients with upper limb amputation. However, allograft rejection has been seen in essentially all reported VCA recipients indicating a requirement for substantial immunosuppressive therapy. Calcineurin inhibitors have served as the centerpiece agent in all reported cases, and CNI‐associated complications associated with the broad therapeutic effects and side effects of calcineurin inhibitors have been similarly common. Recently, belatacept has been approved as a calcineurin inhibitor replacement in kidney transplantation, but to date, its use in VCA has not been reported. Herein, we report on the case of a hand transplant recipient who developed recurrent acute rejection with alloantibody formation and concomitant calcineurin inhibitor nephrotoxicity, all of which resolved upon conversion from a maintenance regimen of tacrolimus, mycophenolate mofetil and steroids to belatacept and sirolimus. This case indicates that belatacept may be a reasonable maintenance immunosuppressive alternative for use in VCA, providing sufficient prophylaxis from rejection with a reduced side effect profile, the latter being particularly relevant for nonlife threatening conditions typically treated by VCA. 相似文献
57.
Bacigalupo A; Broccia G; Corda G; Arcese W; Carotenuto M; Gallamini A; Locatelli F; Mori PG; Saracco P; Todeschini G 《Blood》1995,85(5):1348-1353
Patients with severe aplastic anemia (SAA) and a neutrophil (PMN) count of less than 0.5 x 10(9)/L are exposed to a high risk of early mortality when treated with antilymphocyte globulin (ALG) and steroids, with the major problem being infectious complications. The addition of human recombinant granulocyte colony-stimulating factor (rhG-CSF) to ALG may reduce early mortality by improving neutrophil counts in the short term. To test the feasibility of this approach, the SAA Working Party of the European Group for Blood and Marrow Transplantation (EBMT) designed a pilot study that included rhG-CSF (5 micrograms/kg/d, days 1 through 90), horse ALG (HALG; 15 mg/kg/d, days 1 through 5), methylprednisolone (2 mg/kg/d, days 1 through 5, then tapering the dose), and cyclosporin A (CyA; 5 mg/kg/d orally, days 1 through 180). Patients with newly diagnosed acquired SAA (untreated) and with neutrophil counts of < or = 0.5 x 10(9)/L were eligible. Forty consecutive patients entered this study and are evaluable with a minimum follow up of 120 days: the median age was 16 years (range, 2 to 72 years), the interval from diagnosis to treatment was 24 days, and the median PMN count was 0.19 x 10(9)/L. Twenty-one patients had hemorrhages, and 19 were infected at the time of treatment. Overall, treatment was well tolerated: the median maximum PMN count during rhG- CSF administration was 12 x 10(9)/L (range, 0.4 x 10(9)/L to 44 x 10(9)/L). There were three early deaths (8%) due to infection. Four patients (10%) showed no recovery, whereas 33 patients (82%) had trilineage hematologic reconstitution and became transfusion- independent at a median interval of 115 days from treatment. Median follow up for surviving patients is 428 days (range, 122 to 1,005). Actuarial survival is 92%: 86% and 100% for patients with PMN counts less than 0.2 x 10(9)/L or between 0.2 x 10(9)/L and 0.5 x 10(9)/L, respectively. This study suggests that the addition of rhG-CSF to ALG and CyA is well tolerated, is associated with a low risk of mortality, and offers a good chance of hematologic response. This protocol would appear to be an interesting alternative treatment for SAA patients with a low PMN count who lack an HLA-identical sibling. 相似文献
58.
Tao Huang Jinyan Huang Qibin Qi Yanping Li George A. Bray Jennifer Rood Frank M. Sacks Lu Qi 《Diabetes care》2015,38(3):439-444
OBJECTIVEA common variant rs236918 in the PCSK7 gene has the strongest association with iron homeostasis and is related to insulin resistance. Dietary carbohydrate (CHO) modulates the genetic effect on insulin resistance. We examined whether 2-year weight-loss diets modify the effect of PCSK7 genetic variants on changes in fasting insulin levels and insulin resistance in a randomized, controlled trial.RESULTSDuring the 6-month weight-loss phase, the PCSK7 rs236918 G allele was significantly associated with greater decreases in fasting insulin levels in the high–dietary CHO group (P for interaction = 0.04), while the interaction for changes in HOMA-insulin resistance (HOMA-IR) (P for interaction = 0.06) did not reach significant levels in white subjects. The G allele was significantly associated with a greater decrease in fasting insulin levels and HOMA-IR in response to high dietary CHO levels (P = 0.02 and P = 0.03, respectively). From 6 months to 2 years (weight-regain phase), the interactions became attenuated due to the regaining of weight (P for interactions = 0.08 and 0.06, respectively). In addition, we observed similar and even stronger results in the whole-study samples from the trial.CONCLUSIONSOur data suggest that PCSK7 genotypes may interact with dietary CHO intake on changes in insulin sensitivity in the white Americans. 相似文献
59.
We evaluated weight changes in obese patients at 6‐months after they ended participation in a 12‐month randomised controlled trial in which they received daily placebo, zonisamide 200 mg or zonisamide 400 mg, in addition to lifestyle counselling. Of the originally randomised 225 patients, 218 completed month‐12 when study interventions were discontinued. For the 154 patients who returned for 6‐month follow‐up off‐treatment, weight changes between month‐12 and month‐18 for placebo (n = 53), zonisamide 200 mg (n = 49) and zonisamide 400 mg groups (n = 52) were 0.5 kg [95% confidence interval (CI), ?0.8 to 1.8; 0.7%], 1.5 kg (0.2–2.8; 1.6%; p = 0.26 vs. placebo) and 2.4 kg (1.1–3.7; 2.6%; p = 0.04 vs. placebo), respectively. Our results suggest that although zonisamide 400 mg daily for 12‐months resulted in greater weight loss than with placebo, weight regain after discontinuation of interventions was greater in the zonisamide 400 mg group than placebo group. 相似文献